Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.

The efficacy of ten daily injections of 500 or 500,000 U of recombinant interleukin 2 (IL-2) day-1 given 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid was evaluated in 31 patients with recurrent head and neck squamous cell carcinoma. No toxic effects were noted. One comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortesina, G., De Stefani, A., Galeazzi, E., Cavallo, G. P., Badellino, F., Margarino, G., Jemma, C., Forni, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968846/
https://www.ncbi.nlm.nih.gov/pubmed/8123489

Ejemplares similares

Ejemplares similares